CeriBell, Inc. Common Stock CBLL
HEALTHCARE · MEDICAL DEVICESi
Market dataready · fetched 2026-11-11T13:50:26.619Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:00:01.614041734Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T13:45:37.953615+00:00
CeriBell, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 22.16 | 196.8% | 23.4% | |||
| 25Δ | 23.67 | 168.6% | 18.4% | |||
| 30Δ | 29.59 | 79.1% | 10.3% | 25.01 | 145.5% | 14.0% |
| 35Δ | 29.08 | 81.8% | 9.5% | 25.61 | 138.4% | 12.6% |
| 40Δ | 28.57 | 84.4% | 8.6% | 26.21 | 131.3% | 11.1% |
| 45Δ | 28.06 | 87.0% | 7.8% | 26.81 | 124.1% | 9.7% |
| 50Δ | 27.55 | 89.7% | 6.9% | 27.40 | 117.0% | 8.3% |
| 55Δ | 27.04 | 92.3% | 6.1% | 28.00 | 109.9% | 6.9% |
| 60Δ | 26.53 | 94.9% | 5.2% | 28.60 | 102.7% | 5.5% |
| 65Δ | 26.02 | 97.5% | 4.4% | 29.19 | 95.6% | 4.0% |
| 70Δ | 25.50 | 100.2% | 3.5% | 29.79 | 88.5% | 2.6% |
| 75Δ | 24.99 | 102.8% | 2.7% | 30.83 | 89.0% | 1.8% |
| 80Δ | 23.88 | 103.6% | 2.2% | 32.10 | 93.7% | 1.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 22.16
- IV
- 196.8%
- B/E move
- 23.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 23.67
- IV
- 168.6%
- B/E move
- 18.4%
30Δ
- Pseudo strike
- 29.59
- IV
- 79.1%
- B/E move
- 10.3%
- Pseudo strike
- 25.01
- IV
- 145.5%
- B/E move
- 14.0%
35Δ
- Pseudo strike
- 29.08
- IV
- 81.8%
- B/E move
- 9.5%
- Pseudo strike
- 25.61
- IV
- 138.4%
- B/E move
- 12.6%
40Δ
- Pseudo strike
- 28.57
- IV
- 84.4%
- B/E move
- 8.6%
- Pseudo strike
- 26.21
- IV
- 131.3%
- B/E move
- 11.1%
45Δ
- Pseudo strike
- 28.06
- IV
- 87.0%
- B/E move
- 7.8%
- Pseudo strike
- 26.81
- IV
- 124.1%
- B/E move
- 9.7%
50Δ
- Pseudo strike
- 27.55
- IV
- 89.7%
- B/E move
- 6.9%
- Pseudo strike
- 27.40
- IV
- 117.0%
- B/E move
- 8.3%
55Δ
- Pseudo strike
- 27.04
- IV
- 92.3%
- B/E move
- 6.1%
- Pseudo strike
- 28.00
- IV
- 109.9%
- B/E move
- 6.9%
60Δ
- Pseudo strike
- 26.53
- IV
- 94.9%
- B/E move
- 5.2%
- Pseudo strike
- 28.60
- IV
- 102.7%
- B/E move
- 5.5%
65Δ
- Pseudo strike
- 26.02
- IV
- 97.5%
- B/E move
- 4.4%
- Pseudo strike
- 29.19
- IV
- 95.6%
- B/E move
- 4.0%
70Δ
- Pseudo strike
- 25.50
- IV
- 100.2%
- B/E move
- 3.5%
- Pseudo strike
- 29.79
- IV
- 88.5%
- B/E move
- 2.6%
75Δ
- Pseudo strike
- 24.99
- IV
- 102.8%
- B/E move
- 2.7%
- Pseudo strike
- 30.83
- IV
- 89.0%
- B/E move
- 1.8%
80Δ
- Pseudo strike
- 23.88
- IV
- 103.6%
- B/E move
- 2.2%
- Pseudo strike
- 32.10
- IV
- 93.7%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 67.75% | |
| 79.77% | |
| 80.68% | |
| 78.12% | |
| 97.91% | |
| 59.00% | |
| 60.82% | |
| 62.52% | |
| 67.50% | |
| 65.78% | |
| 69.76% | |
| 73.13% | |
| 73.47% | |
| 69.62% | |
| 70.19% | |
| 67.51% | |
| 69.73% | |
| 75.05% | |
| 75.19% | |
| 70.91% | |
| 64.23% | |
| 80.97% | |
| 82.10% | |
| 69.02% | |
| 69.89% | |
| 67.93% | |
| 69.69% | |
| 64.83% | |
| 69.70% | |
| 67.93% | |
| 59.37% | |
| 70.39% | |
| 65.73% | |
| 66.99% | |
| 70.51% | |
| 76.50% | |
| 69.80% | |
| 67.90% | |
| 85.90% | |
| 106.49% | |
| 67.30% | |
| 64.00% | |
| 63.23% | |
| 64.12% | |
| 66.10% | |
| 67.91% | |
| 64.31% | |
| 65.44% | |
| 64.10% | |
| 69.05% |
Medical Devices
CERS
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in…
More →CLPT
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
More →CNMD
CONMED Corporation, a medical technology company, develops, manufactures and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company…
More →CTKB
Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, delivering innovative cell analysis solutions that advance research in immunology, cancer…
More →CVRX
CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
More →DCTH
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is…
More →